Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Susan Molineaux
|
| gptkbp:collaboratedWith |
gptkb:Incyte_Corporation
|
| gptkbp:developedBy |
CB-839 (telaglenastat)
INCB001158 |
| gptkbp:focusesOn |
oncology
immuno-oncology |
| gptkbp:foundedIn |
2010
|
| gptkbp:founder |
Susan Molineaux
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Calithera Biosciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:status |
filed for bankruptcy in 2023
|
| gptkbp:tradedOn |
NASDAQ:CALA
|
| gptkbp:website |
https://www.calithera.com/
|
| gptkbp:bfsParent |
gptkb:Alta_Partners
gptkb:South_San_Francisco,_California,_USA |
| gptkbp:bfsLayer |
7
|